<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Tirzepatide Watchdog — Blog</title><link>https://tirzepatidewatchdog.com</link><atom:link href="https://tirzepatidewatchdog.com/blog-feed.xml" rel="self" type="application/rss+xml"/><description>Evidence and pricing research on GLP-1 medications, peptides and telehealth care.</description><language>en-us</language><lastBuildDate>Tue, 14 Jul 2026 17:01:43 +0000</lastBuildDate><item><title>Brand GLP-1 Price Collapse 2026: What Changed</title><link>https://tirzepatidewatchdog.com/blog/brand-glp1-price-collapse-2026</link><guid isPermaLink="true">https://tirzepatidewatchdog.com/blog/brand-glp1-price-collapse-2026</guid><description>Zepbound fell to $299. Wegovy to $349. The oral tablet to $149. The price gap that justified compounded GLP-1 has largely closed, and almost nobody is…</description><pubDate>Tue, 14 Jul 2026 17:01:43 +0000</pubDate></item><item><title>Compounded vs Brand GLP-1: The 2026 Decision</title><link>https://tirzepatidewatchdog.com/blog/compounded-vs-brand-decision</link><guid isPermaLink="true">https://tirzepatidewatchdog.com/blog/compounded-vs-brand-decision</guid><description>The compounded case rested on a price gap that has largely closed. Here is how to decide now.</description><pubDate>Tue, 14 Jul 2026 17:01:43 +0000</pubDate></item><item><title>Flat-Rate vs Dose-Escalating GLP-1 Pricing (2026)</title><link>https://tirzepatidewatchdog.com/blog/flat-rate-vs-escalating-glp1</link><guid isPermaLink="true">https://tirzepatidewatchdog.com/blog/flat-rate-vs-escalating-glp1</guid><description>Some providers charge the same price at every dose. Others raise it as you titrate. Over a year, the gap can exceed $3,000.</description><pubDate>Tue, 14 Jul 2026 17:01:43 +0000</pubDate></item><item><title>Tadalafil &amp; Sildenafil: Skip the Compounded Blend</title><link>https://tirzepatidewatchdog.com/blog/generic-pde5-vs-compounded</link><guid isPermaLink="true">https://tirzepatidewatchdog.com/blog/generic-pde5-vs-compounded</guid><description>Both are FDA-approved and available as inexpensive generics. Compounded troches and &#x27;proprietary blends&#x27; offer no demonstrated advantage.</description><pubDate>Tue, 14 Jul 2026 17:01:43 +0000</pubDate></item><item><title>GLP-1 Annual Cost: The Twelve-Month Truth (2026)</title><link>https://tirzepatidewatchdog.com/blog/glp1-annual-cost-truth</link><guid isPermaLink="true">https://tirzepatidewatchdog.com/blog/glp1-annual-cost-truth</guid><description>Monthly figures are how this is marketed. Annual totals are how it is experienced. Every provider, twelve months, all in.</description><pubDate>Tue, 14 Jul 2026 17:01:43 +0000</pubDate></item><item><title>GLP-1 Dose Caps: A Cheap Plan That Cannot Work</title><link>https://tirzepatidewatchdog.com/blog/glp1-dose-cap-warning</link><guid isPermaLink="true">https://tirzepatidewatchdog.com/blog/glp1-dose-cap-warning</guid><description>Noom&#x27;s $199 semaglutide is capped at 0.6mg. The STEP trials used 2.4mg. That is not a discount - it is a different treatment.</description><pubDate>Tue, 14 Jul 2026 17:01:43 +0000</pubDate></item><item><title>GLP-1 Dosing Errors: The Multi-Dose Vial Problem</title><link>https://tirzepatidewatchdog.com/blog/glp1-dosing-errors</link><guid isPermaLink="true">https://tirzepatidewatchdog.com/blog/glp1-dosing-errors</guid><description>The FDA has logged 1,700++ adverse events for compounded semaglutide and 320+ for tirzepatide. Dosing errors from self-measured vials are a recurring…</description><pubDate>Tue, 14 Jul 2026 17:01:43 +0000</pubDate></item><item><title>GLP-1 Insurance Guide: Getting to $25/Month</title><link>https://tirzepatidewatchdog.com/blog/glp1-insurance-guide</link><guid isPermaLink="true">https://tirzepatidewatchdog.com/blog/glp1-insurance-guide</guid><description>If your plan covers Zepbound or Wegovy, a manufacturer savings card can bring it to roughly $25. Nothing on the cash market competes.</description><pubDate>Tue, 14 Jul 2026 17:01:43 +0000</pubDate></item><item><title>How to Verify a Compounding Pharmacy (2026 Guide)</title><link>https://tirzepatidewatchdog.com/blog/how-to-verify-compounding-pharmacy-guide</link><guid isPermaLink="true">https://tirzepatidewatchdog.com/blog/how-to-verify-compounding-pharmacy-guide</guid><description>The pharmacy matters more than the brand on the website. Seven questions, and what the answers tell you.</description><pubDate>Tue, 14 Jul 2026 17:01:43 +0000</pubDate></item><item><title>The GLP-1 Intro-Rate Trap: $179 That Becomes $299</title><link>https://tirzepatidewatchdog.com/blog/intro-rate-trap</link><guid isPermaLink="true">https://tirzepatidewatchdog.com/blog/intro-rate-trap</guid><description>TrimRx advertises $179. MEDVi advertises $179. Both charge $299 from month two. Here is how first-month pricing distorts every comparison table you…</description><pubDate>Tue, 14 Jul 2026 17:01:43 +0000</pubDate></item><item><title>LillyDirect 45-Day Refill Trap: How It Works</title><link>https://tirzepatidewatchdog.com/blog/lillydirect-45-day-trap</link><guid isPermaLink="true">https://tirzepatidewatchdog.com/blog/lillydirect-45-day-trap</guid><description>Zepbound&#x27;s $449 maintenance rate holds only if you refill within 45 days of your last delivery. Miss it and you pay $699.</description><pubDate>Tue, 14 Jul 2026 17:01:43 +0000</pubDate></item><item><title>Microdose GLP-1: A Legal Workaround, Not a Breakthrough</title><link>https://tirzepatidewatchdog.com/blog/microdose-legal-loophole</link><guid isPermaLink="true">https://tirzepatidewatchdog.com/blog/microdose-legal-loophole</guid><description>The industry-wide pivot to microdosing tracks the end of FDA enforcement discretion almost exactly. That is not a coincidence, and nobody selling it…</description><pubDate>Tue, 14 Jul 2026 17:01:43 +0000</pubDate></item><item><title>NAD+ Evidence Review: What Human Trials Show</title><link>https://tirzepatidewatchdog.com/blog/nad-plus-evidence-review</link><guid isPermaLink="true">https://tirzepatidewatchdog.com/blog/nad-plus-evidence-review</guid><description>NAD+ decline with age is well-established cell biology. That supplementing it reverses ageing in humans is not.</description><pubDate>Tue, 14 Jul 2026 17:01:43 +0000</pubDate></item><item><title>GLP-1 Providers With No Membership Fee (2026)</title><link>https://tirzepatidewatchdog.com/blog/no-membership-glp1-providers</link><guid isPermaLink="true">https://tirzepatidewatchdog.com/blog/no-membership-glp1-providers</guid><description>Split billing makes programmes look cheaper than they are. Here is who charges a membership, who does not, and what the true totals are.</description><pubDate>Tue, 14 Jul 2026 17:01:43 +0000</pubDate></item><item><title>ODT GLP-1: No Trial Evidence, Highest Price</title><link>https://tirzepatidewatchdog.com/blog/odt-glp1-no-trial-evidence</link><guid isPermaLink="true">https://tirzepatidewatchdog.com/blog/odt-glp1-no-trial-evidence</guid><description>Compounded ODT tirzepatide and semaglutide have never been tested in a clinical trial - and they cost more than the injection they are meant to replace.</description><pubDate>Tue, 14 Jul 2026 17:01:43 +0000</pubDate></item><item><title>Peptide Evidence: Three Fallacies to Watch For</title><link>https://tirzepatidewatchdog.com/blog/peptide-evidence-fallacies</link><guid isPermaLink="true">https://tirzepatidewatchdog.com/blog/peptide-evidence-fallacies</guid><description>Mouse-to-human transfer, biomarker-for-outcome substitution, and deficiency-to-enhancement transfer. Once you can name them you see them everywhere.</description><pubDate>Tue, 14 Jul 2026 17:01:43 +0000</pubDate></item><item><title>The Brand GLP-1 Retail Trap: 4x to 11x Markups</title><link>https://tirzepatidewatchdog.com/blog/retail-trap-brand-glp1</link><guid isPermaLink="true">https://tirzepatidewatchdog.com/blog/retail-trap-brand-glp1</guid><description>Some telehealth platforms resell brand-name GLP-1s at close to retail while the manufacturer sells the identical drug direct for a fraction. Check…</description><pubDate>Tue, 14 Jul 2026 17:01:43 +0000</pubDate></item><item><title>Semaglutide Salts: Why the Form Matters</title><link>https://tirzepatidewatchdog.com/blog/semaglutide-salts-warning</link><guid isPermaLink="true">https://tirzepatidewatchdog.com/blog/semaglutide-salts-warning</guid><description>Some compounded products use semaglutide sodium or acetate. The FDA has said these are not the same active ingredient as approved semaglutide.</description><pubDate>Tue, 14 Jul 2026 17:01:43 +0000</pubDate></item><item><title>Tirzepatide vs Semaglutide: SURMOUNT-5 Explained</title><link>https://tirzepatidewatchdog.com/blog/tirzepatide-vs-semaglutide-head-to-head</link><guid isPermaLink="true">https://tirzepatidewatchdog.com/blog/tirzepatide-vs-semaglutide-head-to-head</guid><description>SURMOUNT-5 put them against each other directly: −20.2% vs −13.7%. Here is the result, and the two caveats that belong with it.</description><pubDate>Tue, 14 Jul 2026 17:01:43 +0000</pubDate></item><item><title>Stopping GLP-1: Weight Regain and the Real Cost</title><link>https://tirzepatidewatchdog.com/blog/what-happens-when-you-stop-glp1</link><guid isPermaLink="true">https://tirzepatidewatchdog.com/blog/what-happens-when-you-stop-glp1</guid><description>Extension data found roughly two-thirds of lost weight returned within a year of stopping. That changes what the monthly price actually means.</description><pubDate>Tue, 14 Jul 2026 17:01:43 +0000</pubDate></item></channel></rss>